微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 61.01% | 32.07% | 22.88% | 53/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 49.65% | 17.81% | -4.09% | 76/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 51.77% | 20.94% | 3.21% | 71/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 50.16% | 24.76% | 8.58% | 70/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 46.19% | 26.04% | 9.61% | 78/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 42.14% | -8.93% | -1.54% | 97/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 42.81% | -9.28% | 6.48% | 91/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 40.2% | -15.31% | 9.69% | 97/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 36.65% | -21.04% | -20.8% | 102/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 46.28% | 73.06% | -1.92% | 90/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 47.18% | 13.98% | -0.61% | 85/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 47.47% | -6.79% | 2.28% | 86/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 46.41% | -21.54% | 73.57% | 86/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 26.74% | -46.72% | -35.4% | 127/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 41.39% | -21.23% | -18.72% | 93/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 50.93% | -7.89% | -13.9% | 82/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 59.16% | 3.02% | 17.86% | 60/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 50.19% | -6.43% | -4.5% | 83/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 52.55% | -3.64% | -4.96% | 68/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 55.29% | 1.05% | -3.71% | 69/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 57.42% | 6.97% | 7.06% | 58/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 53.64% | -15.01% | -1.65% | 75/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 54.54% | -14.36% | -0.33% | 62/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 54.72% | -16.51% | 1.93% | 64/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 53.68% | -13.32% | -14.93% | 55/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 63.11% | -8.36% | -0.9% | 51/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 63.68% | 139.59% | -2.84% | 38/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 65.54% | 148.9% | 5.82% | 35/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 61.93% | 120.5% | -10.07% | 37/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 68.87% | 126.09% | 159.11% | 37/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 26.58% | -16.59% | 0.94% | 92/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 26.33% | -15.38% | -6.25% | 98/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 28.09% | -2.71% | -7.79% | 89/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 30.46% | 5.94% | -4.41% | 101/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 31.87% | 7.33% | 2.4% | 72/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 31.12% | 6.33% | 7.79% | 77/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 28.87% | 1.64% | 0.4% | 63/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 28.75% | -1.23% | -3.16% | 90/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 29.69% | 2% | 1.45% | 63/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 29.27% | 2% | 3.03% | 70/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 28.4% | 2% | -2.43% | 59/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |